In Depth 18 Jul 2024
Lenacapavir: Can Gilead’s drug end the HIV pandemic?
Discover more about Gilead’s lenacapavir, which recently demonstrated 100% efficacy for HIV prevention in a phase 3 trial.
Gilead
- Latest Posts
News and Trends 20 Jul 2023
Seven pharma companies form alliance to prepare for future pandemics
Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […]
News and Trends 19 Aug 2022
Gilead to acquire remaining worldwide rights of breast cancer drug, Trodelvy
All of Everest Medicine’s development and commercialization rights for a breast cancer drug called Trodelvy have been transferred to American biopharma Gilead Sciences Inc. The transfer of the antibody drug, sacituzumab govitecan treatment, will apply to Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia. In China mainland and Singapore, Trodelvy is […]
News and Trends 4 Mar 2021
Galapagos and Gilead Soldier On After Inflammatory Disease Flops
Clinical and regulatory setbacks have left the star biotech duo Gilead and Galapagos smarting and their stock value bruised in recent months. Yet the pair claim to be well capitalized to weather the storm and determined to do so together. The two companies forged an unusual blockbuster agreement in 2019, valued at around €4.5B ($5.1B), […]
News and Trends 5 Oct 2020
Galapagos’ Arthritis Drug Approved in EU and Japan Amid US Rejection
The recent EU and Japan approvals of the rheumatoid arthritis drug filgotinib contrast with the FDA’s rejection in August. What does this signal for Galapagos, Gilead, and other biotechs working in inflammatory disease? For Galapagos and Gilead, it’s been a rollercoaster few months. In August, the FDA decided against approving their drug filgotinib for treating […]
News and Trends 8 Jul 2020
Remdesivir Becomes the First Covid-19 Treatment Approved in Europe
Remdesivir has received a one-year conditional marketing authorization from the European Commission due to the urgency of the Covid-19 pandemic, which has infected at least 2.5 million people in Europe, and killed more than 500,000. The intravenous drug, manufactured by US pharma company Gilead Sciences, is intended for adults and children over the age of […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 15 Jul 2019
Gilead Pays Billions for Access to Galapagos’ Pipeline
Gilead has launched a 10-year collaboration with the Belgo-Dutch biotech Galapagos, paying at least €4.5B ($5.1B) for commercial rights to Galapagos’s whole pipeline, including a phase III drug for pulmonary fibrosis. As part of the deal, Gilead will pay Galapagos €3.5B ($3.95B) upfront, with a further €1B ($1.1B) in equity investment. In return, Gilead gets […]
News and Trends 3 Jun 2019
Belgian and US Biotechs Team up to Reduce CAR T Side Effects
The diagnostics company Biocartis is collaborating with Kite Pharma to monitor the progress of CAR T-cell therapies in patients to better manage side effects. CAR T-cell therapies have revolutionized the way we treat cancer. Instead of giving the patient a classical drug, companies can inject them with living, genetically engineered cells that kill cancer cells. […]
News and Trends 3 Jan 2019
Austrian Biopharma Reaches First HIV Vaccine Milestone
Hookipa Pharma has reached its first milestone in a partnership deal with US-based CAR T pioneers Gilead Sciences to develop an HIV vaccine using the Austrian company’s arenavirus-based technology. Hookipa’s lead candidate is a prophylactic vaccine for cytomegalovirus, a common infection that can be dangerous in people with weak immune systems, such as those with […]
News and Trends 5 Jul 2017
Galapagos and Gilead Launch the Fifth New Trial for Filgotinib this Year
With the addition of uveitis, Galapagos and Gilead are raising to 10 the number of indications in filgotinib’s clinical pipeline. Galapagos and Gilead clearly have big expectations for filgotinib. The small molecule is already in Phase III for rheumatoid arthritis, Crohn’s disease and ulcerative colitis. The team is now launching a new Phase II trial in […]
News and Trends 14 Feb 2017
Dual HIV Therapy: GSK and Gilead Battle over Whose Drug is the Best
GSK announced Phase III results for dolutegravir, which could reduce triple HIV therapy down to two drugs, but Gilead is trying to prove that its candidate bictegravir is better. GSK and Gilead have announced they will present detailed data backing their candidates for a dual HIV therapy. The battlefield will be the Annual Conference on Retroviruses […]
News and Trends 9 Dec 2016
Galapagos gets another Milestone Payment from Gilead
Galapagos is starting a new PhaseIIb/III clinical trial for ulcerative colitis that has triggered a €9.4M milestone payment from Gilead. Can this partnership beat out its many competitors? Galapagos is one of the few billion-euro biotechs in Europe, boasting top-level partnerships with AbbVie for cystic fibrosis and MorphoSys for inflammatory diseases. The company now has news […]
ADVERTISEMENT